MedTrace Logo

Efficacy, Safety and Acceptability of Nastent™ in Snoring and Obstructive Sleep Apnea

NCT03510403 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2019-08-26

No results posted yet for this study

Summary

This study evaluates the efficacy, the tolerance and the acceptability/compliance of the nasal airway stent, Nastent, for the treatment of mild to moderate OSA and snoring in European adult patients without cardiovascular and/or respiratory comorbidities/disorders.

Conditions

Interventions

DEVICE

nastent™

Snorer and OSA patients (mild or moderate OSA) use the nasal airway stent for sleeping, each night for 1 month.

Sponsors & Collaborators

  • Slb Pharma

    collaborator OTHER

  • nastent.inc

    collaborator UNKNOWN

  • Seven Dreamers Europe SAS

    lead INDUSTRY

Principal Investigators

  • Marc Blumen, MD · Foch Hospital, Suresnes, FRANCE

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-12
Primary Completion
2019-07-25
Completion
2019-07-25

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03510403 on ClinicalTrials.gov